Patents by Inventor Christian Furlan FREGUIA

Christian Furlan FREGUIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS
    Publication number: 20230310558
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Application
    Filed: April 14, 2023
    Publication date: October 5, 2023
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • Treatment delivery system and method
    Publication number: 20230285508
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20230277466
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 7, 2023
    Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
  • Alkaline phosphatase agents for treatment of radiation disorders
    Patent number: 11654184
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 23, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Christian Furlan Freguia, Sheila Connelly
  • Intestinal alkaline phosphatase formulations
    Patent number: 11638699
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 2, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Ray Stapleton, Michael Kaleko, Christian Furlan Freguia, Steven Hubert, Cristina Freire, James Gubbins
  • INTESTINAL ALKALINE PHOSPHATASE-BASED TREATMENTS OF METABOLIC DISORDERS
    Publication number: 20220257726
    Abstract: The present invention relates, inter alia, to combination therapies of specific commensal gastrointestinal bacteria with therapeutic intestinal alkaline phosphatases for the treatment of disease, such as metabolic disorders. The present invention further relates to compositions comprising the combination of specific commensal gastrointestinal bacteria with therapeutic alkaline phosphatases and use of the compositions in the treatment of metabolic disorders.
    Type: Application
    Filed: July 16, 2020
    Publication date: August 18, 2022
    Inventor: Christian FURLAN FREGUIA
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS
    Publication number: 20220241383
    Abstract: The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 4, 2022
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS
    Publication number: 20220202914
    Abstract: The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).
    Type: Application
    Filed: May 5, 2020
    Publication date: June 30, 2022
    Inventors: Christian FURLAN FREGUIA, Michael KALEKO
  • Alkaline phosphatase agents for treatment of neurodevelopmental disorders
    Patent number: 11338020
    Abstract: Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: May 24, 2022
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Christian Furlan Freguia, Sheila Connelly
  • ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20210220448
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Inventors: Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
  • Alkaline phosphatase formulations
    Patent number: 10987410
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 27, 2021
    Assignee: Synthetic Biologics, Inc.
    Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS
    Publication number: 20210060139
    Abstract: The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
    Type: Application
    Filed: January 8, 2019
    Publication date: March 4, 2021
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20210030686
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS
    Publication number: 20210023182
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 28, 2021
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
    Publication number: 20190315642
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: June 3, 2019
    Publication date: October 17, 2019
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Compositions for in vivo expression of therapeutic sequences in the microbiome
    Patent number: 10351452
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 16, 2019
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20180326018
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 15, 2018
    Inventors: Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
  • Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
    Patent number: 9676641
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 13, 2017
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
    Publication number: 20160367701
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 22, 2016
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • THERAPEUTIC PHAGES AND METHODS FOR DELIVERY OF NUCLEIC ACIDS FOR THERAPEUTIC USES
    Publication number: 20160160186
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: January 26, 2015
    Publication date: June 9, 2016
    Inventors: Todd Bernard PARSLEY, Christian Furlan FREGUIA